Polyganics wins $1m grant for dura sealant patch study
Summary
The grant is a great recognition of the potential of this application of our synthetic polymers, and we are pleased to have benefitted from the skills and expertise of both the BTI and Syncom in its development. The work has important implications for improved recovery following brain surgery, including helping to prevent potentially fatal complications such as meningitis,” Polyganics CEO Rudy Mareel said in a press release. Polyganics said it is finalizing preparations for a clinical study looking to explore the safety and performance of the dura patch in humans. The recent successful animal studies of the dura sealant patch were very promising, and we expect to see similarly positive results in humans in the clinical studies next year,” BTI research project lead Dr. Tristan van Doormaal of the University Medical Center Utrecht said in prepared remarks. Last June, Polyganics won CE Mark approval in the European Union for its absorbable, implantable Neurocap device designed to reduce neuroma formation and facilitate tissue repair.